Insider Buying: Fractyl Health, Inc. (NASDAQ:GUTS) Director Acquires 16,129 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) Director William Bradley purchased 16,129 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were purchased at an average cost of $1.26 per share, with a total value of $20,322.54. Following the completion of the acquisition, the director now directly owns 16,129 shares of the company's stock, valued at $20,322.54. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Fractyl Health Price Performance

Fractyl Health stock traded up $0.01 during mid-day trading on Friday, reaching $1.24. The company had a trading volume of 125,031 shares, compared to its average volume of 295,703. Fractyl Health, Inc. has a 1 year low of $1.16 and a 1 year high of $8.37. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The company has a market capitalization of $60.66 million and a P/E ratio of -0.10. The stock's 50-day simple moving average is $1.60 and its 200-day simple moving average is $2.14.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.08). On average, equities analysts predict that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Remove Ads

Institutional Trading of Fractyl Health

Large investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA boosted its position in Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company's stock worth $2,646,000 after acquiring an additional 49,289 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company's stock worth $204,000 after acquiring an additional 29,262 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company's stock worth $53,000 after acquiring an additional 7,397 shares during the last quarter. HighTower Advisors LLC acquired a new stake in Fractyl Health during the third quarter worth approximately $38,000. Finally, State Street Corp boosted its position in Fractyl Health by 129.4% during the third quarter. State Street Corp now owns 113,415 shares of the company's stock worth $287,000 after acquiring an additional 63,968 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley dropped their target price on shares of Fractyl Health from $18.00 to $10.00 and set an "overweight" rating for the company in a report on Monday, February 3rd.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.